Septerna Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEPN research report →
Range $43 – $60
Price Chart
About the company
Septerna, Inc. , a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease.
- CEO
- Jeffrey T. Finer
- IPO
- 2024
- Employees
- 134
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on SEPN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.84B
- P/E
- -29.93
- PEG
- 0.16
- P/S
- 19.07
- P/B
- 4.23
- EV/EBITDA
- -32.64
- Div Yield
- 0.00%
- Gross Margin
- 99.56%
- Op Margin
- -76.23%
- Net Margin
- -61.29%
- ROE
- -14.98%
- ROIC
- -14.19%
Latest fiscal year · YoY change
- Revenue
- $45.95M+4174.5%
- Gross Profit
- $45.95M+4174.5%
- Op Income
- $-80,797,000
- Net Income
- $-48,879,000+31.9%
- EPS
- $-1.10+43.0%
- OCF Growth
- +263.3%
- FCF Growth
- +257.6%
- 52W High
- $53.34
- 52W Low
- $22.78
- 50D MA
- $40.67
- 200D MA
- $33.43
- Beta
- 2.20
- RSI (14)
- 40
- Avg Volume
- 382.64K
No earnings-call transcripts are available for SEPN yet.
- Free Float
- 41.9%
- Shares Outstanding
- 47.55M
- Float Shares
- 19.91M
of shares held by institutions
167 13F filers
Buy/sell ratio 0.11. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 7.00M | 0 |
| Trv Gp V, LLC | 6.22M | 0 |
| Driehaus Capital Management LLC | 4.43M | ▲ 37.49K |
| Trv Gp Vi, LLC | 4.21M | 0 |
| Samsara Biocapital, LLC | 3.15M | 0 |
| Goldman Sachs Group Inc | 3.06M | ▲ 156.34K |
| Blackrock, Inc. | 2.07M | ▲ 142.51K |
| Siren, L.L.C. | 1.70M | ▼ 200.00K |
| Vanguard Group Inc | 1.51M | ▼ 10.56K |
| Vanguard Capital Management LLC | 1.35M | ▲ 132.62K |
| Primecap Management Co | 1.35M | ▲ 186.88K |
| Avoro Capital Advisors LLC | 1.34M | 0 |
Held by 238 ETFs
Biggest fund positions in SEPN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Labrucherie Gil M | sell | 15,815 |
| Nov 16, 26 | Labrucherie Gil M | sell | 3,485 |
| Nov 16, 26 | Labrucherie Gil M | sell | 700 |
| Nov 12, 26 | Finer Jeffrey | other | 18,500 |
| Nov 12, 26 | Finer Jeffrey | sell | 5,600 |
| Nov 12, 26 | Finer Jeffrey | sell | 5,300 |
| Nov 12, 26 | Finer Jeffrey | sell | 2,800 |
| Nov 12, 26 | Finer Jeffrey | sell | 2,823 |
| Nov 12, 26 | Finer Jeffrey | sell | 1,977 |
| Nov 12, 26 | Finer Jeffrey | other | 18,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SEPN coverage
Recent articles, reports, and earnings notes.
No research on SEPN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SEPN report →Septerna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?
fool.com · Nov 15
Septerna: The SEP-479 Readout Could Unlock Further Upside
seekingalpha.com · Nov 11
Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 9
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 9
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
globenewswire.com · Nov 4
Septerna to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 3
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares of Stock
defenseworld.net · Oct 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.